| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 68 | 2022 | 3534 | 5.040 |
Why?
|
| Osteoporosis | 38 | 2022 | 1600 | 3.170 |
Why?
|
| Menopause | 21 | 2023 | 1640 | 2.410 |
Why?
|
| Teriparatide | 11 | 2014 | 227 | 2.260 |
Why?
|
| Testosterone | 33 | 2020 | 2470 | 1.940 |
Why?
|
| Absorptiometry, Photon | 26 | 2022 | 1736 | 1.910 |
Why?
|
| Osteoporosis, Postmenopausal | 11 | 2016 | 393 | 1.780 |
Why?
|
| Radius | 12 | 2021 | 440 | 1.650 |
Why?
|
| Goserelin | 6 | 2020 | 127 | 1.630 |
Why?
|
| Estradiol | 23 | 2019 | 1932 | 1.590 |
Why?
|
| Cystic Fibrosis | 7 | 2022 | 1274 | 1.580 |
Why?
|
| Libido | 4 | 2020 | 119 | 1.580 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2023 | 407 | 1.430 |
Why?
|
| Bone Density Conservation Agents | 11 | 2022 | 796 | 1.380 |
Why?
|
| Fractures, Bone | 15 | 2022 | 2041 | 1.310 |
Why?
|
| Tibia | 7 | 2018 | 1065 | 1.180 |
Why?
|
| Bone and Bones | 11 | 2021 | 2560 | 1.080 |
Why?
|
| Body Composition | 13 | 2022 | 2419 | 1.080 |
Why?
|
| Fragile X Mental Retardation Protein | 2 | 2016 | 116 | 1.030 |
Why?
|
| Bone Diseases, Metabolic | 6 | 2022 | 409 | 1.020 |
Why?
|
| Leuprolide | 7 | 2017 | 315 | 0.960 |
Why?
|
| Androstenedione | 5 | 2002 | 131 | 0.960 |
Why?
|
| Gonadotropin-Releasing Hormone | 17 | 2017 | 1153 | 0.950 |
Why?
|
| Women's Health | 17 | 2022 | 2056 | 0.870 |
Why?
|
| Lumbar Vertebrae | 19 | 2022 | 1868 | 0.860 |
Why?
|
| Alendronate | 5 | 2010 | 173 | 0.860 |
Why?
|
| Bone Remodeling | 11 | 2018 | 580 | 0.820 |
Why?
|
| Menstrual Cycle | 5 | 2020 | 536 | 0.730 |
Why?
|
| Aminophenols | 1 | 2021 | 86 | 0.710 |
Why?
|
| Vitamin D | 9 | 2019 | 3291 | 0.690 |
Why?
|
| Muscle Strength | 2 | 2013 | 619 | 0.660 |
Why?
|
| Antineoplastic Agents, Hormonal | 8 | 2019 | 1529 | 0.640 |
Why?
|
| Anabolic Agents | 3 | 2010 | 253 | 0.640 |
Why?
|
| Hypogonadism | 14 | 2016 | 801 | 0.640 |
Why?
|
| Premenopause | 10 | 2022 | 1038 | 0.590 |
Why?
|
| Quinolones | 1 | 2021 | 377 | 0.580 |
Why?
|
| Parathyroid Hormone | 10 | 2012 | 1797 | 0.560 |
Why?
|
| Bone Resorption | 7 | 2013 | 720 | 0.550 |
Why?
|
| Eunuchism | 1 | 2016 | 19 | 0.530 |
Why?
|
| Climacteric | 4 | 2004 | 57 | 0.520 |
Why?
|
| Reproduction | 2 | 2020 | 646 | 0.520 |
Why?
|
| Perimenopause | 4 | 2017 | 141 | 0.520 |
Why?
|
| Vitamin D Deficiency | 7 | 2019 | 1379 | 0.500 |
Why?
|
| Femur Neck | 9 | 2022 | 312 | 0.490 |
Why?
|
| Ergocalciferols | 2 | 2015 | 110 | 0.490 |
Why?
|
| Prescriptions | 2 | 2021 | 388 | 0.480 |
Why?
|
| Aromatase Inhibitors | 6 | 2019 | 511 | 0.480 |
Why?
|
| Middle Aged | 96 | 2022 | 220352 | 0.470 |
Why?
|
| Postmenopause | 8 | 2021 | 2509 | 0.470 |
Why?
|
| Histamine H2 Antagonists | 1 | 2015 | 167 | 0.440 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2013 | 25 | 0.440 |
Why?
|
| Fibroblast Growth Factors | 2 | 2012 | 869 | 0.440 |
Why?
|
| Hormones | 7 | 2017 | 867 | 0.430 |
Why?
|
| Adult | 95 | 2022 | 219994 | 0.420 |
Why?
|
| Spinal Neoplasms | 6 | 2015 | 716 | 0.410 |
Why?
|
| Nafarelin | 4 | 1999 | 27 | 0.400 |
Why?
|
| Fractures, Spontaneous | 10 | 2017 | 231 | 0.390 |
Why?
|
| Bone Cements | 4 | 2006 | 324 | 0.390 |
Why?
|
| Adipose Tissue | 4 | 2022 | 3301 | 0.390 |
Why?
|
| Female | 108 | 2023 | 391270 | 0.380 |
Why?
|
| Puberty, Delayed | 3 | 1999 | 121 | 0.380 |
Why?
|
| Adiposity | 2 | 2020 | 1858 | 0.370 |
Why?
|
| Spinal Fractures | 7 | 2011 | 702 | 0.370 |
Why?
|
| Menstruation | 5 | 2020 | 307 | 0.360 |
Why?
|
| Gonadotropins | 6 | 1991 | 241 | 0.360 |
Why?
|
| Humans | 161 | 2023 | 760621 | 0.360 |
Why?
|
| Infertility, Female | 1 | 2016 | 759 | 0.360 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 1717 | 0.350 |
Why?
|
| Gastric Bypass | 2 | 2018 | 829 | 0.350 |
Why?
|
| Polymethyl Methacrylate | 3 | 2006 | 131 | 0.350 |
Why?
|
| Drug Utilization | 2 | 2016 | 1195 | 0.350 |
Why?
|
| Obesity, Morbid | 3 | 2018 | 1287 | 0.350 |
Why?
|
| Follicle Stimulating Hormone | 16 | 2019 | 725 | 0.350 |
Why?
|
| Spinal Cord Compression | 2 | 2015 | 235 | 0.340 |
Why?
|
| Antihypertensive Agents | 2 | 2019 | 2061 | 0.340 |
Why?
|
| Proton Pump Inhibitors | 1 | 2015 | 551 | 0.340 |
Why?
|
| Prostatic Neoplasms | 11 | 2011 | 11345 | 0.330 |
Why?
|
| Estrogens | 5 | 2017 | 1520 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2018 | 20509 | 0.320 |
Why?
|
| Longitudinal Studies | 23 | 2020 | 14495 | 0.320 |
Why?
|
| Cohort Studies | 29 | 2021 | 41335 | 0.320 |
Why?
|
| Phosphates | 3 | 2012 | 772 | 0.320 |
Why?
|
| Male | 96 | 2022 | 359744 | 0.320 |
Why?
|
| Prescription Drugs | 1 | 2016 | 630 | 0.320 |
Why?
|
| Orthopedic Procedures | 3 | 2008 | 1263 | 0.310 |
Why?
|
| Peptide Fragments | 3 | 2019 | 5125 | 0.300 |
Why?
|
| Osteocalcin | 7 | 2012 | 274 | 0.290 |
Why?
|
| Decompression, Surgical | 2 | 2014 | 604 | 0.290 |
Why?
|
| Gonadal Steroid Hormones | 9 | 2014 | 701 | 0.290 |
Why?
|
| Injections, Subcutaneous | 4 | 2020 | 680 | 0.280 |
Why?
|
| Spine | 9 | 2018 | 1111 | 0.280 |
Why?
|
| Androgens | 5 | 2019 | 1291 | 0.280 |
Why?
|
| Spinal Osteophytosis | 1 | 2006 | 30 | 0.280 |
Why?
|
| Osteoporotic Fractures | 2 | 2022 | 409 | 0.280 |
Why?
|
| Spinal Canal | 1 | 2006 | 41 | 0.270 |
Why?
|
| Dietary Supplements | 6 | 2019 | 3392 | 0.270 |
Why?
|
| Health Behavior | 2 | 2016 | 2622 | 0.260 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2017 | 132 | 0.260 |
Why?
|
| Laminectomy | 1 | 2006 | 224 | 0.250 |
Why?
|
| Trinucleotide Repeats | 2 | 2016 | 257 | 0.250 |
Why?
|
| Nitriles | 3 | 2005 | 956 | 0.250 |
Why?
|
| Aging | 5 | 2020 | 8651 | 0.250 |
Why?
|
| Spinal Fusion | 3 | 2014 | 1281 | 0.250 |
Why?
|
| Patient Compliance | 6 | 2017 | 2688 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2020 | 10827 | 0.240 |
Why?
|
| Bone Development | 5 | 2005 | 472 | 0.240 |
Why?
|
| Pain, Intractable | 1 | 2006 | 132 | 0.240 |
Why?
|
| Aged | 50 | 2021 | 169152 | 0.240 |
Why?
|
| Bone Neoplasms | 6 | 2017 | 2532 | 0.240 |
Why?
|
| Ovary | 3 | 2023 | 958 | 0.240 |
Why?
|
| Vitamins | 2 | 2012 | 1634 | 0.230 |
Why?
|
| Follow-Up Studies | 15 | 2022 | 39261 | 0.230 |
Why?
|
| Diphosphonates | 4 | 2007 | 638 | 0.230 |
Why?
|
| Case-Control Studies | 7 | 2022 | 22053 | 0.230 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 1005 | 0.220 |
Why?
|
| Triazoles | 3 | 2014 | 904 | 0.220 |
Why?
|
| Spinal Diseases | 2 | 2008 | 559 | 0.220 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 3150 | 0.220 |
Why?
|
| Insulin Resistance | 5 | 2022 | 3959 | 0.210 |
Why?
|
| Epitestosterone | 1 | 2002 | 3 | 0.210 |
Why?
|
| United States | 22 | 2021 | 72461 | 0.200 |
Why?
|
| Aged, 80 and over | 24 | 2020 | 58995 | 0.200 |
Why?
|
| Administration, Cutaneous | 2 | 2020 | 713 | 0.200 |
Why?
|
| Overweight | 1 | 2013 | 2421 | 0.200 |
Why?
|
| Endometriosis | 3 | 1999 | 874 | 0.190 |
Why?
|
| Anilides | 1 | 2004 | 409 | 0.190 |
Why?
|
| Estranes | 1 | 2000 | 2 | 0.190 |
Why?
|
| Calcium | 5 | 2006 | 5725 | 0.190 |
Why?
|
| Nandrolone | 1 | 2000 | 17 | 0.190 |
Why?
|
| Collagen Type I | 6 | 2014 | 616 | 0.190 |
Why?
|
| Penile Erection | 1 | 2020 | 100 | 0.180 |
Why?
|
| Cervical Vertebrae | 1 | 2006 | 978 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 4 | 2012 | 7475 | 0.170 |
Why?
|
| Prospective Studies | 12 | 2022 | 54303 | 0.170 |
Why?
|
| Luteinizing Hormone | 13 | 2017 | 820 | 0.170 |
Why?
|
| Nonprescription Drugs | 1 | 2000 | 118 | 0.170 |
Why?
|
| Young Adult | 12 | 2022 | 58741 | 0.170 |
Why?
|
| Drug Contamination | 1 | 2000 | 152 | 0.170 |
Why?
|
| Gels | 1 | 2020 | 419 | 0.160 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 987 | 0.160 |
Why?
|
| Body Fat Distribution | 1 | 2020 | 243 | 0.160 |
Why?
|
| Body Mass Index | 9 | 2022 | 12914 | 0.160 |
Why?
|
| Treatment Outcome | 20 | 2020 | 65017 | 0.160 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 6498 | 0.160 |
Why?
|
| Body Weight | 4 | 2019 | 4611 | 0.150 |
Why?
|
| Reference Values | 5 | 2016 | 4925 | 0.150 |
Why?
|
| Hip | 2 | 2021 | 251 | 0.150 |
Why?
|
| Mass Screening | 2 | 2012 | 5423 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2012 | 6218 | 0.150 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2021 | 446 | 0.150 |
Why?
|
| Spinal Cord Injuries | 2 | 2015 | 924 | 0.140 |
Why?
|
| Administration, Topical | 1 | 2019 | 697 | 0.140 |
Why?
|
| Orthopedics | 3 | 2022 | 892 | 0.140 |
Why?
|
| Estrone | 4 | 2017 | 232 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2014 | 1189 | 0.140 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 1737 | 0.130 |
Why?
|
| Blood Chemical Analysis | 2 | 2014 | 437 | 0.130 |
Why?
|
| Prediabetic State | 1 | 2022 | 550 | 0.130 |
Why?
|
| Galactose | 1 | 2017 | 297 | 0.130 |
Why?
|
| Immunoassay | 2 | 2012 | 746 | 0.130 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2015 | 78 | 0.130 |
Why?
|
| Receptors, Histamine H2 | 1 | 2015 | 18 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 3448 | 0.130 |
Why?
|
| Time Factors | 11 | 2015 | 40165 | 0.120 |
Why?
|
| Collagen | 4 | 2013 | 2636 | 0.120 |
Why?
|
| Eating | 1 | 2022 | 1539 | 0.120 |
Why?
|
| Femur | 3 | 2012 | 1302 | 0.120 |
Why?
|
| Calcitriol | 3 | 2006 | 297 | 0.120 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 3 | 1990 | 36 | 0.120 |
Why?
|
| Hormone Replacement Therapy | 2 | 2015 | 755 | 0.120 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 1 | 2014 | 8 | 0.120 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 25942 | 0.120 |
Why?
|
| Urinalysis | 3 | 2002 | 368 | 0.110 |
Why?
|
| Androgen Antagonists | 3 | 2011 | 1442 | 0.110 |
Why?
|
| Tibial Fractures | 1 | 2017 | 264 | 0.110 |
Why?
|
| Glycosylation | 1 | 2017 | 1096 | 0.110 |
Why?
|
| Osteogenesis | 3 | 2014 | 1271 | 0.110 |
Why?
|
| Multivariate Analysis | 6 | 2014 | 12159 | 0.110 |
Why?
|
| Patient Education as Topic | 3 | 2008 | 2315 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2019 | 965 | 0.100 |
Why?
|
| Motor Activity | 3 | 2014 | 2687 | 0.100 |
Why?
|
| Spondylolisthesis | 1 | 2014 | 173 | 0.100 |
Why?
|
| Peptides | 6 | 2014 | 4354 | 0.100 |
Why?
|
| Sex Hormone-Binding Globulin | 6 | 2019 | 546 | 0.100 |
Why?
|
| Obesity | 2 | 2019 | 12922 | 0.100 |
Why?
|
| Propensity Score | 2 | 2019 | 1928 | 0.100 |
Why?
|
| Adolescent | 15 | 2022 | 87810 | 0.100 |
Why?
|
| Alkaline Phosphatase | 3 | 2003 | 865 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2021 | 2566 | 0.100 |
Why?
|
| Risk Factors | 13 | 2019 | 74359 | 0.100 |
Why?
|
| Drug Combinations | 2 | 2009 | 2025 | 0.100 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2013 | 432 | 0.100 |
Why?
|
| Finite Element Analysis | 1 | 2013 | 428 | 0.090 |
Why?
|
| Administration, Oral | 4 | 2002 | 4035 | 0.090 |
Why?
|
| Sex Factors | 6 | 2017 | 10547 | 0.090 |
Why?
|
| Hypercalcemia | 1 | 2014 | 421 | 0.090 |
Why?
|
| Fertility | 1 | 2016 | 773 | 0.090 |
Why?
|
| Weight-Bearing | 1 | 2013 | 518 | 0.090 |
Why?
|
| Japan | 2 | 2013 | 1369 | 0.090 |
Why?
|
| Prognosis | 4 | 2020 | 29658 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2017 | 1016 | 0.090 |
Why?
|
| Diet | 2 | 2006 | 8010 | 0.090 |
Why?
|
| Pituitary Gland | 4 | 1989 | 637 | 0.090 |
Why?
|
| Age Factors | 7 | 2015 | 18416 | 0.090 |
Why?
|
| Logistic Models | 5 | 2019 | 13314 | 0.090 |
Why?
|
| Fractures, Compression | 1 | 2011 | 129 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1259 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2016 | 3615 | 0.080 |
Why?
|
| Risk | 3 | 2019 | 9631 | 0.080 |
Why?
|
| Blood Glucose | 4 | 2022 | 6381 | 0.080 |
Why?
|
| Procollagen | 2 | 2006 | 188 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 1523 | 0.080 |
Why?
|
| China | 2 | 2013 | 2339 | 0.080 |
Why?
|
| Embalming | 1 | 1988 | 13 | 0.080 |
Why?
|
| Substance Abuse Detection | 2 | 2002 | 301 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2016 | 9716 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2008 | 3986 | 0.080 |
Why?
|
| Boston | 4 | 2015 | 9280 | 0.080 |
Why?
|
| Pelvic Bones | 2 | 2018 | 270 | 0.070 |
Why?
|
| Risk Assessment | 6 | 2019 | 24123 | 0.070 |
Why?
|
| Linear Models | 3 | 2014 | 5877 | 0.070 |
Why?
|
| Gynecomastia | 1 | 1988 | 87 | 0.070 |
Why?
|
| Anthropometry | 2 | 2002 | 1348 | 0.070 |
Why?
|
| Retreatment | 1 | 2009 | 600 | 0.070 |
Why?
|
| Chorionic Gonadotropin | 1 | 1989 | 457 | 0.070 |
Why?
|
| Versicans | 1 | 2007 | 40 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2002 | 1636 | 0.070 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 2717 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 2890 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2016 | 12293 | 0.070 |
Why?
|
| Pharmacoepidemiology | 2 | 2019 | 350 | 0.070 |
Why?
|
| Weight Gain | 2 | 2019 | 2347 | 0.070 |
Why?
|
| Cyclic AMP | 1 | 2010 | 1456 | 0.070 |
Why?
|
| Seasons | 1 | 2012 | 1522 | 0.070 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2008 | 161 | 0.070 |
Why?
|
| Body Constitution | 2 | 2004 | 273 | 0.070 |
Why?
|
| Quality of Life | 4 | 2006 | 13308 | 0.070 |
Why?
|
| Endocrinology | 1 | 2012 | 443 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2017 | 2511 | 0.070 |
Why?
|
| Exercise | 2 | 2022 | 5787 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 7806 | 0.060 |
Why?
|
| Physicians, Family | 1 | 2007 | 349 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3465 | 0.060 |
Why?
|
| Bone Diseases | 1 | 2009 | 419 | 0.060 |
Why?
|
| Aromatase | 1 | 2005 | 147 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2010 | 1428 | 0.060 |
Why?
|
| Canada | 3 | 2015 | 2128 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 4541 | 0.060 |
Why?
|
| Palliative Care | 4 | 2017 | 3607 | 0.060 |
Why?
|
| Anorexia Nervosa | 1 | 2014 | 1361 | 0.060 |
Why?
|
| Osteoprotegerin | 1 | 2005 | 177 | 0.060 |
Why?
|
| Pennsylvania | 4 | 2008 | 615 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 17790 | 0.060 |
Why?
|
| Length of Stay | 2 | 2015 | 6479 | 0.060 |
Why?
|
| Tosyl Compounds | 1 | 2004 | 112 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 3 | 2011 | 2529 | 0.060 |
Why?
|
| Waist Circumference | 2 | 2021 | 926 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3804 | 0.050 |
Why?
|
| Weight Loss | 1 | 2015 | 2686 | 0.050 |
Why?
|
| Pain | 3 | 2016 | 5066 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 2512 | 0.050 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2003 | 101 | 0.050 |
Why?
|
| Pregnanediol | 2 | 2017 | 18 | 0.050 |
Why?
|
| Patient Selection | 3 | 2015 | 4283 | 0.050 |
Why?
|
| Control Groups | 1 | 2002 | 104 | 0.050 |
Why?
|
| Androsterone | 2 | 2001 | 14 | 0.050 |
Why?
|
| Etiocholanolone | 2 | 2001 | 7 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 585 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2006 | 1206 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2014 | 2985 | 0.050 |
Why?
|
| Corpus Luteum | 2 | 2017 | 81 | 0.050 |
Why?
|
| Adiponectin | 1 | 2008 | 1115 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2004 | 13630 | 0.050 |
Why?
|
| Calcifediol | 2 | 2015 | 161 | 0.050 |
Why?
|
| Medicare | 2 | 2012 | 6786 | 0.050 |
Why?
|
| Glucuronides | 1 | 2001 | 20 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2012 | 2283 | 0.050 |
Why?
|
| Hip Joint | 3 | 2014 | 1006 | 0.050 |
Why?
|
| Syndrome | 1 | 2008 | 3280 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2016 | 3528 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 3455 | 0.050 |
Why?
|
| Drug Administration Schedule | 5 | 2007 | 4899 | 0.050 |
Why?
|
| Safety | 1 | 2006 | 1148 | 0.050 |
Why?
|
| Propylamines | 3 | 1966 | 161 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2007 | 2234 | 0.050 |
Why?
|
| Sodium | 1 | 2006 | 1594 | 0.050 |
Why?
|
| HIV Wasting Syndrome | 1 | 2001 | 97 | 0.050 |
Why?
|
| Imidazoles | 1 | 2007 | 1180 | 0.050 |
Why?
|
| Dihydrotestosterone | 1 | 2001 | 195 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1630 | 0.050 |
Why?
|
| Insulin | 1 | 2015 | 6597 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2008 | 1826 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2013 | 3726 | 0.040 |
Why?
|
| Monoamine Oxidase Inhibitors | 3 | 1966 | 155 | 0.040 |
Why?
|
| Life Style | 2 | 2002 | 3896 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 854 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2023 | 611 | 0.040 |
Why?
|
| Family Practice | 1 | 2003 | 510 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3696 | 0.040 |
Why?
|
| New England | 1 | 2003 | 1050 | 0.040 |
Why?
|
| Calcium Gluconate | 1 | 1999 | 22 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 1988 | 1486 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 15840 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2004 | 597 | 0.040 |
Why?
|
| Pirenzepine | 1 | 1999 | 116 | 0.040 |
Why?
|
| Blood Pressure | 3 | 2019 | 8525 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 2 | 2006 | 2696 | 0.040 |
Why?
|
| Phenotype | 2 | 2016 | 16546 | 0.040 |
Why?
|
| Inpatients | 2 | 2022 | 2581 | 0.040 |
Why?
|
| Joint Instability | 1 | 2006 | 795 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2003 | 1754 | 0.040 |
Why?
|
| Health Maintenance Organizations | 1 | 2001 | 660 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 9276 | 0.040 |
Why?
|
| Lipids | 2 | 2008 | 3336 | 0.040 |
Why?
|
| Calcium, Dietary | 1 | 2001 | 531 | 0.040 |
Why?
|
| Extremities | 2 | 2017 | 867 | 0.040 |
Why?
|
| Incidence | 2 | 2015 | 21392 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2002 | 1134 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2007 | 2029 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2022 | 1161 | 0.040 |
Why?
|
| Feedback | 2 | 1991 | 791 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 1978 | 118 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2006 | 989 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2017 | 165 | 0.040 |
Why?
|
| Pineal Gland | 1 | 1978 | 157 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2005 | 2208 | 0.040 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3598 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2009 | 2165 | 0.040 |
Why?
|
| Retrospective Studies | 9 | 2021 | 80372 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2015 | 12427 | 0.040 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1997 | 87 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2023 | 904 | 0.040 |
Why?
|
| Sodium Oxybate | 1 | 1997 | 33 | 0.030 |
Why?
|
| Sports | 1 | 2003 | 700 | 0.030 |
Why?
|
| Fertility Agents, Female | 1 | 2017 | 101 | 0.030 |
Why?
|
| Accidental Falls | 2 | 2019 | 1056 | 0.030 |
Why?
|
| Ontario | 1 | 2017 | 404 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3839 | 0.030 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 608 | 0.030 |
Why?
|
| Sunlight | 1 | 1998 | 337 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 1722 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2022 | 1548 | 0.030 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1999 | 257 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2015 | 40 | 0.030 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2017 | 275 | 0.030 |
Why?
|
| Light | 2 | 1978 | 1344 | 0.030 |
Why?
|
| Iproniazid | 2 | 1966 | 8 | 0.030 |
Why?
|
| Abbreviated Injury Scale | 1 | 2014 | 49 | 0.030 |
Why?
|
| Amino Acids | 1 | 2001 | 1714 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1989 | 1032 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 3726 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1989 | 1975 | 0.030 |
Why?
|
| Gonads | 1 | 2014 | 109 | 0.030 |
Why?
|
| Porosity | 1 | 2014 | 349 | 0.030 |
Why?
|
| Health Services Research | 1 | 2001 | 1810 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 3763 | 0.030 |
Why?
|
| Child | 4 | 2021 | 79806 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6315 | 0.030 |
Why?
|
| Osteolysis | 2 | 2007 | 274 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2000 | 2192 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2005 | 240 | 0.030 |
Why?
|
| Thyrotropin | 2 | 2003 | 832 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 2943 | 0.030 |
Why?
|
| Self Efficacy | 2 | 2008 | 630 | 0.030 |
Why?
|
| Radioimmunoassay | 3 | 1989 | 866 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 1999 | 1341 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 1818 | 0.030 |
Why?
|
| Calibration | 1 | 1994 | 816 | 0.020 |
Why?
|
| Testolactone | 1 | 1991 | 5 | 0.020 |
Why?
|
| Quinoxalines | 1 | 2014 | 297 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1791 | 0.020 |
Why?
|
| Human Growth Hormone | 1 | 1996 | 638 | 0.020 |
Why?
|
| Glucocorticoids | 2 | 2008 | 2145 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2015 | 1683 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 2543 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2017 | 1479 | 0.020 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 1990 | 95 | 0.020 |
Why?
|
| Women | 1 | 2012 | 225 | 0.020 |
Why?
|
| Medical Records | 1 | 1996 | 1407 | 0.020 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 21025 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 15289 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 1928 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 3334 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1998 | 6238 | 0.020 |
Why?
|
| Iodobenzoates | 1 | 1989 | 10 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 1991 | 221 | 0.020 |
Why?
|
| Radiography | 2 | 2011 | 6965 | 0.020 |
Why?
|
| Age Distribution | 2 | 2005 | 2893 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 1989 | 123 | 0.020 |
Why?
|
| Periodicity | 4 | 1990 | 348 | 0.020 |
Why?
|
| Fracture Healing | 1 | 2011 | 438 | 0.020 |
Why?
|
| Testis | 2 | 1989 | 794 | 0.020 |
Why?
|
| Viscera | 1 | 1989 | 138 | 0.020 |
Why?
|
| Algorithms | 1 | 2009 | 13981 | 0.020 |
Why?
|
| Prevalence | 2 | 2012 | 15687 | 0.020 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1988 | 69 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 1603 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2008 | 173 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1988 | 163 | 0.020 |
Why?
|
| Etidronic Acid | 1 | 2007 | 63 | 0.020 |
Why?
|
| Sleep | 2 | 2021 | 4751 | 0.020 |
Why?
|
| Parathyroid Neoplasms | 1 | 2008 | 241 | 0.020 |
Why?
|
| Reoperation | 1 | 2017 | 4291 | 0.020 |
Why?
|
| Isocarboxazid | 1 | 1966 | 7 | 0.020 |
Why?
|
| Tranylcypromine | 1 | 1966 | 30 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 4902 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2003 | 4647 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 1999 | 3061 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1988 | 1385 | 0.020 |
Why?
|
| Body Height | 1 | 2012 | 1570 | 0.020 |
Why?
|
| Calcitonin | 1 | 2007 | 330 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2006 | 157 | 0.020 |
Why?
|
| Sexual Maturation | 1 | 1986 | 260 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 6360 | 0.020 |
Why?
|
| Chickens | 1 | 2007 | 860 | 0.010 |
Why?
|
| Educational Status | 1 | 2012 | 2515 | 0.010 |
Why?
|
| Densitometry | 1 | 2004 | 151 | 0.010 |
Why?
|
| Hand | 1 | 2009 | 903 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 1067 | 0.010 |
Why?
|
| Angiography | 1 | 1989 | 1605 | 0.010 |
Why?
|
| Lung | 1 | 2022 | 9994 | 0.010 |
Why?
|
| Fibronectins | 1 | 2007 | 722 | 0.010 |
Why?
|
| Pharmacology | 1 | 1963 | 99 | 0.010 |
Why?
|
| Polypharmacy | 1 | 2005 | 307 | 0.010 |
Why?
|
| Body Weights and Measures | 1 | 2003 | 208 | 0.010 |
Why?
|
| Prostate | 1 | 2011 | 1793 | 0.010 |
Why?
|
| Monoamine Oxidase | 1 | 1963 | 178 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 3529 | 0.010 |
Why?
|
| Consensus | 1 | 2012 | 3113 | 0.010 |
Why?
|
| Toxicology | 1 | 1963 | 103 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 2005 | 430 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 8552 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2011 | 1956 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1963 | 276 | 0.010 |
Why?
|
| Cadaver | 1 | 2006 | 1345 | 0.010 |
Why?
|
| Metabolism | 1 | 1963 | 193 | 0.010 |
Why?
|
| Mesocricetus | 2 | 1978 | 252 | 0.010 |
Why?
|
| Survival Rate | 1 | 2015 | 12808 | 0.010 |
Why?
|
| Hydrazines | 1 | 1963 | 224 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2015 | 5425 | 0.010 |
Why?
|
| Economics, Pharmaceutical | 1 | 2001 | 88 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 2061 | 0.010 |
Why?
|
| Injections | 1 | 2004 | 830 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1999 | 5889 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2003 | 15697 | 0.010 |
Why?
|
| Physical Endurance | 1 | 2003 | 363 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 2295 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2007 | 3607 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2007 | 3094 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1988 | 2210 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 3800 | 0.010 |
Why?
|
| Community Networks | 1 | 2001 | 201 | 0.010 |
Why?
|
| Rats | 2 | 1988 | 23711 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2001 | 474 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2011 | 3905 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 1374 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 4013 | 0.010 |
Why?
|
| Biopsy | 1 | 2011 | 6771 | 0.010 |
Why?
|
| Health Surveys | 1 | 2009 | 4063 | 0.010 |
Why?
|
| Copulation | 1 | 1978 | 12 | 0.010 |
Why?
|
| Registries | 1 | 2015 | 8469 | 0.010 |
Why?
|
| Proteins | 1 | 2014 | 6029 | 0.010 |
Why?
|
| Transfection | 1 | 2007 | 5781 | 0.010 |
Why?
|
| Estrus | 1 | 1978 | 70 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2004 | 1666 | 0.010 |
Why?
|
| Disease Progression | 1 | 2015 | 13502 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2014 | 14372 | 0.010 |
Why?
|
| Castration | 1 | 1978 | 153 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 3618 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 2475 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 36290 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 2802 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2001 | 504 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 961 | 0.010 |
Why?
|
| Nursing Homes | 1 | 2005 | 1082 | 0.010 |
Why?
|
| Cricetinae | 2 | 1978 | 2427 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2001 | 755 | 0.010 |
Why?
|
| Mice | 3 | 2014 | 81208 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2004 | 1268 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2001 | 680 | 0.010 |
Why?
|
| Osmolar Concentration | 2 | 1989 | 660 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 2897 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 2256 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2002 | 882 | 0.010 |
Why?
|
| Depression | 1 | 2016 | 8044 | 0.010 |
Why?
|
| Organic Chemistry Phenomena | 2 | 1966 | 4 | 0.010 |
Why?
|
| Vigabatrin | 1 | 1997 | 88 | 0.010 |
Why?
|
| Chemistry, Organic | 2 | 1966 | 9 | 0.010 |
Why?
|
| Radiology | 1 | 2010 | 2102 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2362 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 2640 | 0.010 |
Why?
|
| Animals | 5 | 2014 | 167963 | 0.010 |
Why?
|
| Chemistry | 2 | 1966 | 348 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2002 | 1521 | 0.010 |
Why?
|
| Muscle, Skeletal | 2 | 2004 | 4925 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 3484 | 0.010 |
Why?
|
| Chemical Phenomena | 2 | 1966 | 508 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1994 | 20080 | 0.010 |
Why?
|
| Succinate-Semialdehyde Dehydrogenase | 1 | 1997 | 96 | 0.010 |
Why?
|
| Language Development Disorders | 1 | 1997 | 192 | 0.010 |
Why?
|
| Smoking | 1 | 2012 | 9073 | 0.010 |
Why?
|
| Metabolism, Inborn Errors | 1 | 1997 | 285 | 0.010 |
Why?
|
| Health Education | 1 | 2001 | 1049 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 4433 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1996 | 568 | 0.010 |
Why?
|
| Research | 1 | 1963 | 1974 | 0.010 |
Why?
|
| Progesterone | 1 | 1978 | 742 | 0.010 |
Why?
|
| Motor Skills | 1 | 1997 | 520 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 1999 | 1131 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 5201 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1988 | 18957 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 12531 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 4081 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 5075 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 10551 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10446 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1997 | 1132 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1996 | 1817 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 16939 | 0.010 |
Why?
|
| Myocardium | 1 | 1963 | 4700 | 0.010 |
Why?
|
| Diatrizoate | 1 | 1989 | 81 | 0.010 |
Why?
|
| Puberty | 1 | 1972 | 498 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 1997 | 1504 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 8056 | 0.000 |
Why?
|
| Liver | 1 | 1963 | 7509 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 13262 | 0.000 |
Why?
|
| Spermatogenesis | 1 | 1986 | 257 | 0.000 |
Why?
|
| Spectrum Analysis | 1 | 1966 | 453 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1990 | 1168 | 0.000 |
Why?
|
| Biological Assay | 1 | 1986 | 630 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1997 | 12965 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 11712 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1999 | 6796 | 0.000 |
Why?
|
| Child, Preschool | 3 | 1997 | 42063 | 0.000 |
Why?
|
| Ejaculation | 1 | 1978 | 59 | 0.000 |
Why?
|
| Drug Implants | 1 | 1978 | 230 | 0.000 |
Why?
|
| Heart Rate | 1 | 1989 | 4179 | 0.000 |
Why?
|
| Pregnancy | 1 | 1978 | 29749 | 0.000 |
Why?
|
| Brain | 1 | 1963 | 26951 | 0.000 |
Why?
|
| Sex Chromosomes | 1 | 1976 | 101 | 0.000 |
Why?
|
| Contrast Media | 1 | 1989 | 5305 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1989 | 6414 | 0.000 |
Why?
|
| Disorders of Sex Development | 1 | 1976 | 128 | 0.000 |
Why?
|
| Infant | 1 | 1997 | 36060 | 0.000 |
Why?
|
| Sleep, REM | 1 | 1972 | 593 | 0.000 |
Why?
|
| Wakefulness | 1 | 1972 | 1255 | 0.000 |
Why?
|